Antibodies for bioanalysis and drug monitoring of denosumab and biosimilars

Develop highly selective and sensitive PK and ADA assays for denosumab (Prolia, Xgeva) using our range of ready-made anti-idiotypic antibodies.

  • Inhibitory and non-inhibitory antibodies specific to denosumab
  • Fully human surrogate positive control or calibrator
  • Sequence defined, well characterized reagents with secure supply
  • Recombinant production, stringent quality control for batch to batch consistency
  • Non-animal-derived antibodies, reducing the use of animals in science

Table 1. Antibodies Specific to Denosumab.

Specificity
Binding Type

Catalog Number

Clone

Format

Affinity* KD, nM

Assay Recommendation

Product Details

Denosumab Inhibitory Type 1

HCA288

AbD26296

Fab-FH1

7.1

PK bridging ELISA

Order HCA288

HCA280
HCA280P

AbD26295_hIgG1

hIgG1

HRP

1.8

PK bridging ELISA

ADA control

Order HCA280
Order HCA280P

HCA281

AbD26296_hIgG1

hIgG1

7.1

ADA control

Order HCA281

HCA282

AbD26862_hIgG1

hIgG1

0.8

ADA control

Order HCA282

Denosumab & Denosumab-RANKL

Non-Inhibitory

Type 2

HCA283
HCA283P

AbD26781_hIgG1

hIgG1

HRP

19 (Denosumab)
17 (Denosumab/
RANKL complex)

PK bridging ELISA

Order HCA283
Order HCA283P

* Affinity measured in the monovalent Fab format
1 Monovalent Fab antibody DYKDDDDK- and His-6-tags


Anti-Denosumab Inhibitory Antibodies (Type 1)

Type 1 anti-denosumab antibodies inhibit the binding of the drug denosumab to its target, RANKL (receptor activator of nuclear factor kappa-B ligand). They are ideal for development of a pharmacokinetic (PK) bridging ELISA to measure free drug. In fully human IgG1 format they are available in high, medium and lower affinity, and are suitable as a surrogate positive control or calibrator for an anti-drug antibody (ADA) assay.


Anti-Denosumab Non-Inhibitory Antibody (Type 2)

The type 2 anti-denosumab antibody binds to the denosumab idiotope, but does not inhibit the binding of denosumab to RANKL.


ELISA Protocols to Get You Started

PK Bridging ELISA


Fig. 1. Denosumab PK bridging ELISA using antibodies HCA280 or HCA282 and HCA283P.

Fig. 1. Denosumab PK bridging ELISA using antibodies HCA280 or HCA282 and HCA283P.

Schematic image of PK bridging ELISA with inhibitory (capture) and non-inhibitory (detection) antibodies. Anti-idiotypic capture antibody, Ig format (blue), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format, labeled with HRP.

Schematic image of PK bridging ELISA with inhibitory (capture) and non-inhibitory (detection) antibodies. Anti-idiotypic capture antibody, Ig format (blue), monoclonal antibody drug (gold), anti-idiotypic detection antibody, Ig format, labeled with HRP.


ADA Bridging ELISA


Fig. 2. Denosumab ADA bridging ELISA using antibody HCA280, HCA281 or HCA282.

Fig. 2. Denosumab ADA bridging ELISA using antibody HCA280, HCA281 or HCA282.

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).

Schematic image of ADA bridging assay. Monoclonal antibody drug as capture antibody and detection antibody labeled with HRP (gold), fully human anti-idiotypic antibody, Ig format (blue).


Related Products



Resources



Licensed Use: For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.